Last reviewed 2026-04-23 · How we verify

HL301(Experimental)

HL301 is an experimental drug that targets the PD-1/PD-L1 pathway to enhance anti-tumor immune response.

HL301 is an experimental drug that targets the PD-1/PD-L1 pathway to enhance anti-tumor immune response. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Melanoma.

At a glance

Mechanism of action

By inhibiting the PD-1/PD-L1 interaction, HL301 aims to restore the body's natural ability to recognize and attack cancer cells. This mechanism is thought to be effective in various types of cancer, including non-small cell lung cancer and melanoma.

Approved indications

• Metastatic non-small cell lung cancer, PD-L1 positive
• Melanoma

Common side effects

• Fatigue
• Diarrhea
• Nausea
• Rash
• Pneumonitis

Key clinical trials

• Study to Evaluate Efficacy and Safety of Bronpass Tab. in Patients With Chronic Obstructive Pulmonary Disease (PHASE2)
• Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients (PHASE2)
• A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Umkamin Tab in Acute Bronchitis Patients (PHASE3)
• A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Placebo in Acute Bronchitis Patients (PHASE2)
• A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.